Scribd
Upload
1K views1 page

Zidovudine Nursing

This clinical medication worksheet provides information on the antiviral drug zidovudine (AZT) including its classification, dosing, side effects, interactions, contraindications, and key nursing considerations. AZT is a nucleoside reverse transcriptase inhibitor with an onset of 0.5-1.5 hours, duration of 4 hours, and usual adult dose of 600 mg per day divided into multiple doses. Common side effects include bone marrow suppression, gastrointestinal issues, and headaches. Lab monitoring is needed to watch for decreases in white blood cells or hemoglobin. The patient should be educated on monitoring for side effects and continuing safe practices to prevent HIV transmission.

Uploaded by

sanderson
Copyright
© Attribution Non-Commercial (BY-NC)
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as RTF or read online on Scribd
1K views1 page

Zidovudine Nursing

This clinical medication worksheet provides information on the antiviral drug zidovudine (AZT) including its classification, dosing, side effects, interactions, contraindications, and key nursing considerations. AZT is a nucleoside reverse transcriptase inhibitor with an onset of 0.5-1.5 hours, duration of 4 hours, and usual adult dose of 600 mg per day divided into multiple doses. Common side effects include bone marrow suppression, gastrointestinal issues, and headaches. Lab monitoring is needed to watch for decreases in white blood cells or hemoglobin. The patient should be educated on monitoring for side effects and continuing safe practices to prevent HIV transmission.

Uploaded by

sanderson
Copyright
© Attribution Non-Commercial (BY-NC)
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as RTF or read online on Scribd
You are on page 1/ 1

Clinical Form 2 :CLINICAL MEDICATION WORKSHEET

Allergies: NKDA
Generic name Trade name Classification/Action (therapeutic effects for this patient)
Zidovudine AZT Antiviral; nucleoside reverse transcriptase inhibitor

Peak Onset Duration Dose (usual adult range)


0.5-1.5 h Unkown 4hr. 600 mg/day in divided doses 100x4, 200x3, 300x2

For IV meds (list incompatibilities with other Common side effects


meds/solutions) (>1%) Body as a whole: fever, dyspnea, malaise, weakness, myalgia,
Lansoprazole myopathy. CNS: headache, insomnia, dizziness, paresthesias, mild confusion,
anxiety, restlessness, agitation. GI: nausea, diarrhea, vomiting, anorexia, GI
pain. Hematologic: Bone marrow depression, granulocytopenia, and anemia.
Respiratory: Cough, wheezing. Skin: rash, itching, diaphoresis.

Medication alterations of lab values (ie-increased liver enzymes)


Watch CBC for decreased Granulocytes

Contraindications/warnings/Interactions (this patient) Interactions with other patient drugs or herbal medicines
Contraindications: Life threatening allergic reactions to any Acetaminophen ganciclovir, interferon-alfa may enhance bone marrow
of the components of the drug; lactic acidosis; pregnancy suppression; atovaquone, amphotericin B, asprin, dapsome,
(category C), lactation. Cautious use: impaired renal or doxorubicin, fluconazole, flycytosine, indomethacin, interferon alfa,
hepatic function, alcoholism; anemia; chemotherapy; methadone, pentamidine, vincristine, valproic acid may increase risk
radiation therapy; bone marrow depression. of AZT toxicity; probenecid will decrease AZT elimination, resulting in
increased serum levels and thus toxicity; Nelfinavir, rifampin, ritonavir
may decrease zidovudine (AZT) concentrations; other antiretroviral
agents may cause lactic acidosis and severe hapatomegaly with
steatosis; stavudine, doxorubicin may antagonize AZT effects.

Key nursing assessment/interventions/patient teaching before, during, and after administration medication
Evaluate Pt. at least weekly during the first month of therapy. Lab tests: baseline and frequent (at least every 2 weeks) blood counts,
CD4 (T4) lymphocyte count to detect hematologic toxicity. Myelosuppresion results in anemia, which commonly occurs after 4-6 wk
of therapy, and granulocytopenia in 6-8 wk. Frequently, both respond to dosage adjustment. Significant anemia (Hgb <7.5 g/dL or
reduction >25% of baseline value), or granulocyte count <750/mm3 (or reduction >50% of baseline) may require temporary
interruption of therapy and transfusions. Monitor for common adverse effects, especially severe headache, nausea, and myalgia. Pt.
and Family education: Contact physician proptly if health status worsens or any unusual symptoms develop. Understand that this
drug is not a cure for HIV infection; you will continue to be at risk for opportunistic infections. Do not share drugs with others; take
drug exactly as prescribed. Drug does not reduce the risk of transmission of HIV infection through out the body fluids

You might also like